Blade Therapeutics is a biopharmaceutical company that is focused on developing cutting-edge treatments for fibrotic and neurodegenerative diseases that impact millions of people worldwide.
The company specializes in novel biological pathways, such as autotaxin/LPA and calpain biology, which are foundational to cell- and tissue-damage responses associated with fibrotic and neurodegenerative diseases. This focused approach offers the potential to produce disease-modifying, life-saving therapies.
Since its founding in 2015, the company has assembled critical leadership expertise and a world-class network of scientific, pharmaceutical, and clinical advisors to enable efficient and successful drug development. Blade Therapeutics is advancing a differentiated pipeline of oral, small-molecule therapies, including a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains, which are designed for the potential treatment of lung, liver and cardiac fibrosis, or neurodegenerative diseases.
CEO, Blade Therapeutics
I first met the OneVentures team in July 2018. They quickly impressed me with their broad knowledge and capabilities.
Shortly afterwards, they led Blade Therapeutics‘ Series C round. It has been a pleasure to build the company with the support of Paul, Sarah, Michelle, and Gabriel, and their LP’s over the past 3 years. The fund is a true value add investor with deep connections to academic institutions and opinion leaders.